SOUTHLAKE, Texas, Nov. 14, 2022 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases, today announced a $33 million bridge financing consisting of a $23 million SAFE (Simple Agreement for Future Equity) offering and $10 million pursuant to the first tranche of a $30 million term loan with Oxford Finance LLC (“Oxford”). The […]
Financial
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on […]
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
— Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical […]
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2022, and recent business highlights. Recent Highlights Progress Continued […]
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates. “The Company had several notable deliverables this quarter […]
Cardio Diagnostics Holdings Inc CEO Meesha Dogan, Accepted into Forbes Technology Council
Forbes Technology Council Is an Invitation-Only Community for World-Class CIOs, CTOs, and Technology Executives. CHICAGO–(BUSINESS WIRE)–Meesha Dogan, PhD, the CEO of Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives. Cardio Diagnostics is a biotechnology […]
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third […]
Acutus Medical Reports Third Quarter 2022 Financial Results
CARLSBAD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2022. Recent Updates: Reported revenue of $3.6 million in the […]
HeartBeam Reports Third Quarter 2022 Financial Results
HeartBeam AIMI™ Platform Technology for use in Diagnosing Heart Attacks Submitted to FDA for Clearance Company on Track for Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, in Q4 2022 AIMIGo Technology Receives Two Additional Patents Company Plans to Broaden Product Portfolio Pipeline with Smartwatch Connectivity Management to Host […]
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, […]
Recent
Johnson & Johnson Enters Agreement to Acquire Atraverse Medical
Advanced Bifurcation Systems Inc. Acquires Svelte Medical Systems, Inc.
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Popular
- No commented posts yet